TEST (Trial of Eczema allergy Screening Tests): protocol for feasibility randomised controlled trial of allergy tests in children with eczema, including economic scoping and nested qualitative study.
allergy
clinical trials
eczema
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
09 05 2019
09 05 2019
Historique:
entrez:
12
5
2019
pubmed:
12
5
2019
medline:
2
6
2020
Statut:
epublish
Résumé
Early onset eczema is associated with food allergy, and allergic reactions to foods can cause acute exacerbations of eczema. Parents often pursue dietary restrictions as a way of managing eczema and seek allergy testing for their children to guide dietary management. However, it is unclear whether test-guided dietary management improves eczema symptoms, and whether the practice causes harm through reduced use of conventional eczema treatment or unnecessary dietary restrictions. The aim of the Trial of Eczema allergy Screening Tests Study is to determine the feasibility of conducting a trial comparing food allergy testing and dietary advice versus usual care, for the management of eczema in children. Design: A single centre, two-group, individually randomised, feasibility randomised controlled trial (RCT) with economic scoping and a nested qualitative study. General Practioner (GP) surgeries in the west of England. children aged over 3 months and less than 5 years with mild to severe eczema. allergy testing (structured allergy history and skin prick tests) or usual care. Sample size and outcome measures: we aim to recruit 80 participants and follow them up using 4-weekly questionnaires for 24 weeks. Nested qualitative study: We will conduct ~20 interviews with parents of participating children, 5-8 interviews with parents who decline or withdraw from the trial and ~10 interviews with participating GPs. Economic scoping: We will gather data on key costs and outcomes to assess the feasibility of carrying out a cost-effectiveness analysis in a future definitive trial. The study has been reviewed by the Health Research Authority and given a favourable opinion by the NHS REC (West Midlands - South Birmingham Research Ethics Committee, Reference Number 18/WM/0124). Findings will be submitted for presentation at conferences and written up for publication in peer-reviewed journals, which may include mixed-method triangulation and integration of the quantitative and qualitative findings. ISRCTN15397185; Pre-results.
Sections du résumé
BACKGROUND
Early onset eczema is associated with food allergy, and allergic reactions to foods can cause acute exacerbations of eczema. Parents often pursue dietary restrictions as a way of managing eczema and seek allergy testing for their children to guide dietary management. However, it is unclear whether test-guided dietary management improves eczema symptoms, and whether the practice causes harm through reduced use of conventional eczema treatment or unnecessary dietary restrictions. The aim of the Trial of Eczema allergy Screening Tests Study is to determine the feasibility of conducting a trial comparing food allergy testing and dietary advice versus usual care, for the management of eczema in children.
METHODS AND ANALYSIS
Design: A single centre, two-group, individually randomised, feasibility randomised controlled trial (RCT) with economic scoping and a nested qualitative study.
SETTING
General Practioner (GP) surgeries in the west of England.
PARTICIPANTS
children aged over 3 months and less than 5 years with mild to severe eczema.
INTERVENTIONS
allergy testing (structured allergy history and skin prick tests) or usual care. Sample size and outcome measures: we aim to recruit 80 participants and follow them up using 4-weekly questionnaires for 24 weeks. Nested qualitative study: We will conduct ~20 interviews with parents of participating children, 5-8 interviews with parents who decline or withdraw from the trial and ~10 interviews with participating GPs. Economic scoping: We will gather data on key costs and outcomes to assess the feasibility of carrying out a cost-effectiveness analysis in a future definitive trial.
ETHICS AND DISSEMINATION
The study has been reviewed by the Health Research Authority and given a favourable opinion by the NHS REC (West Midlands - South Birmingham Research Ethics Committee, Reference Number 18/WM/0124). Findings will be submitted for presentation at conferences and written up for publication in peer-reviewed journals, which may include mixed-method triangulation and integration of the quantitative and qualitative findings.
TRIAL REGISTRATION
ISRCTN15397185; Pre-results.
Identifiants
pubmed: 31076476
pii: bmjopen-2018-028428
doi: 10.1136/bmjopen-2018-028428
pmc: PMC6527983
doi:
Banques de données
ISRCTN
['ISRCTN15397185']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e028428Subventions
Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: MJR: No financial interests; convenes the NIHR SPCR Allergy working group; and was a member of the NICE Quality Standard 44 for Atopic eczema in under 12s and RCPCH “Care pathway for children with eczema” groups. LW: Direct – financial: write articles, attend round table infant formula company meetings and present at sponsored lectures relating to food allergy; received infant formula company sponsorship to attend national/international allergy related conferences/ meetings. Runs a private practice (Food Allergy Nottingham Service Ltd, 2013-) in addition to NHS role (Feb 2012-). BDA cow’s milk allergy course facilitator (2018-). Direct – non-financial: member of RCPCH faculty for tier 3 paediatric allergy course (2018-); member of Allergy UK health advisory board (2015-); member of iMAP implementation team (2017-); produce food allergy related dietary information for BDA food allergy group (2014-); NICE Expert adviser relating to paediatric food allergy and gastro-oesophageal reflux (2017-2020); previous member of NICE food allergy guidelines GDG and RCPCH food allergy care pathway (2010-2011). RJB has received honoraria for participating in advisory boards for ALK-Abello who manufacture allergy diagnostics and treatments, and DBV technologies who manufacture a food allergy treatment.
Références
Pediatr Allergy Immunol. 1998 Feb;9(1):13-9
pubmed: 9560837
Allergy. 2017 Mar;72(3):453-461
pubmed: 27670637
Allergy. 2009 Feb;64(2):258-64
pubmed: 19178405
J Pediatr. 1998 Jan;132(1):132-6
pubmed: 9470014
Exp Dermatol. 2001 Feb;10(1):11-8
pubmed: 11168575
Br J Dermatol. 2016 Jul;175(1):69-79
pubmed: 27436240
Br J Gen Pract. 2012 Apr;62(597):e261-7
pubmed: 22520913
Clin Exp Allergy. 2015 Jan;45(1):255-64
pubmed: 25210971
Br J Dermatol. 2013 Mar;168(3):577-82
pubmed: 22963149
J Am Acad Dermatol. 2014 Feb;70(2):338-51
pubmed: 24290431
Trials. 2014 Jul 03;15:264
pubmed: 24993581
Clin Transl Allergy. 2013 Feb 01;3(1):3
pubmed: 23369181
Stat Med. 1995 Sep 15;14(17):1933-40
pubmed: 8532986
Arch Dermatol. 2004 Dec;140(12):1513-9
pubmed: 15611432
JAMA. 2010 May 12;303(18):1848-56
pubmed: 20460624
Appl Health Econ Health Policy. 2011 May 1;9(3):157-69
pubmed: 21506622
Br J Dermatol. 2005 Aug;153(2):372-7
pubmed: 16086752
J Allergy Clin Immunol. 2004 May;113(5):832-6
pubmed: 15131563
Qual Life Res. 2013 Feb;22(1):173-83
pubmed: 22302618
BMJ Open. 2018 Feb 15;8(2):e019633
pubmed: 29449296
Br J Dermatol. 2001 Jan;144(1):104-10
pubmed: 11167690
J Allergy Clin Immunol. 2007 Dec;120(6):1389-98
pubmed: 17910890
Arch Dis Child. 2011 Nov;96 Suppl 2:i19-24
pubmed: 22053062
J Dtsch Dermatol Ges. 2009 Mar;7(3):265-71
pubmed: 19371249
Allergy. 2012 Sep;67(9):1111-7
pubmed: 22844983
Clin Exp Allergy. 1999 Jan;29(1):91-6
pubmed: 10051707
Br J Dermatol. 2013 Oct;169(4):760-8
pubmed: 23909890
Pharmacoeconomics. 2012 Aug 1;30(8):729-47
pubmed: 22788262
Clin Exp Dermatol. 2019 Oct;44(7):e235-e237
pubmed: 30834551
Allergy. 2016 Nov;71(11):1620-1625
pubmed: 27232584
BMJ Open. 2015 Apr 08;5(4):e006339
pubmed: 25854963
BMJ Open. 2018 Nov 18;8(11):e022861
pubmed: 30455386
J Adv Nurs. 2013 Nov;69(11):2493-501
pubmed: 23528163
Am J Clin Dermatol. 2009;10(5):287-300
pubmed: 19658441
Br J Dermatol. 2013 Dec;169(6):1326-32
pubmed: 24024631
Qual Health Res. 2016 Nov;26(13):1753-1760
pubmed: 26613970
Trials. 2017 Jul 21;18(1):343
pubmed: 28732519
PLoS One. 2016 Mar 15;11(3):e0150205
pubmed: 26978655
Br J Gen Pract. 2018 Feb;68(667):e73-e80
pubmed: 29335327
J Allergy Clin Immunol. 2012 Dec;130(6):1260-74
pubmed: 23195525